Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Oak Ridge Investments LLC

Oak Ridge Investments LLC reduced its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 3.5% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 58,220 shares of the biopharmaceutical company’s stock after selling 2,120 shares during the period. Oak Ridge Investments LLC’s holdings in Halozyme Therapeutics were worth $2,783,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. GAMMA Investing LLC boosted its holdings in Halozyme Therapeutics by 67.7% during the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 350 shares during the period. Skandinaviska Enskilda Banken AB publ acquired a new stake in shares of Halozyme Therapeutics during the second quarter worth about $49,000. Toth Financial Advisory Corp purchased a new position in shares of Halozyme Therapeutics in the third quarter valued at approximately $57,000. FSC Wealth Advisors LLC acquired a new position in shares of Halozyme Therapeutics in the third quarter valued at approximately $65,000. Finally, Park Place Capital Corp increased its stake in Halozyme Therapeutics by 828.1% during the 3rd quarter. Park Place Capital Corp now owns 1,355 shares of the biopharmaceutical company’s stock worth $78,000 after buying an additional 1,209 shares during the period. 97.79% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Piper Sandler boosted their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. HC Wainwright increased their price target on Halozyme Therapeutics from $68.00 to $70.00 and gave the company a “buy” rating in a research report on Friday, January 10th. JMP Securities boosted their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research report on Friday, November 1st. Finally, Wells Fargo & Company dropped their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $60.89.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00. Following the transaction, the director now owns 43,611 shares of the company’s stock, valued at $2,180,986.11. The trade was a 18.65 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 2.70% of the stock is currently owned by insiders.

Halozyme Therapeutics Trading Down 1.0 %

Shares of Halozyme Therapeutics stock opened at $54.80 on Friday. The company has a fifty day simple moving average of $49.62 and a 200-day simple moving average of $54.11. Halozyme Therapeutics, Inc. has a 12-month low of $33.15 and a 12-month high of $65.53. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. The stock has a market cap of $6.97 billion, a price-to-earnings ratio of 18.15, a PEG ratio of 0.40 and a beta of 1.24.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.